Main menu

Press Release

Celltrion completes filing procedure for approval of Remsima in Japan


Celltrion completes filing procedure for approval of Remsima in Japan
Filed for MHLW approval, anticipates product launch in 2014
- Japan is the second largest market of Remsima’s originator drug in the world, with sales of  approximately USD 1billion

Celltrion (KOSDAQ: 068270) announced today that the company has completed filing procedure of Remsima (Project code: CT-P13) to obtain Japan's Ministry of Health, Labour and Welfare (MHLW) approval.

Celltrion jointly conducted clinical trial in Japan with its partner company, Nippon Kayaku. Last July, Celltrion officially completed these clinical trials in Japan. Celltrion expects to launch Remsima in the Japanese market within 2014 as approval procedure usually takes around a year in Japan.

Remicade®, the originator product of Remsima, is the most successful TNF antagonist treatment antibody in terms of market share in Japan and its sales have peaked at 90 billion Yen last year. Japan is the second largest market for Remicade® following the USA.

An official from Nippon Kayaku elaborated, “The Japanese approval for Remsima will be good news not only for patients in Japan who previously had limited access to advanced therapeutics, but also for their families and their healthcare providers. As Remsima has already successfully received approval from the EMA, the approval process in Japan is expected to proceed smoothly.”

 Last August, Celltrion received MAA approval for 31 individual European countries and anticipate sales to begin as early as this September. 

위로 가기